Ulcerative colitis is a chronic inflammatory condition of the colon, 
characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main 
treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor 
necrosis factor alpha (TNF-α) antibodies including infliximab, adalimumab, and 
golimumab. Golimumab, a new anti-TNF-α agent has been recently approved for 
patients with moderate to severe ulcerative colitis. Its efficacy and safety has 
been demonstrated in line with infliximab and adalimumab in preclinical and 
clinical studies. This review will focus on golimumab therapy in ulcerative 
colitis.